What is Dulaglutide?

Category: Prescription Drugs

Most popular types: Trulicity T2DM Phase III REWIND Study (Dulaglutide)

false

Dulaglutide is a once-weekly injection for the treatment of type 2 diabetes. It is a member of glucagon-like peptide-1 (GLP-1) receptor agonists, which act as a hormone that helps normalize blood sugar levels.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 0
Mild 3
None 17

Commonly reported side effects and conditions associated with Dulaglutide

Side effect Patients Percentage
Decreased appetite 2
Nausea 2
Frequent urination 1
Headaches 1
Low blood sugar (hypoglycemia) 1

Dosages

Based on patients currently taking Dulaglutide

Dosage Patients Percentage
1.5 mg weekly 9
3 mg weekly 3
0.5 mL weekly 1
0.75 mg weekly 1
75 mg weekly 1

Why patients stopped taking Dulaglutide

Multiple reasons could be selected

Reason Patients Percentage
Change in health plan coverage 1
Other 1
See all 2 patients who've stopped taking Dulaglutide

Duration

Currently taking Dulaglutide

Duration Patients Percentage
6 months - 1 year 4
1 - 2 years 4
2 - 5 years 6
5 - 10 years 1

Stopped taking Dulaglutide

Duration Patients Percentage
1 - 6 months 1
2 - 5 years 1
Adherence
Adherence Evaluations Percentage
Always 13
Usually 4
Sometimes 3
Never taken as prescribed 0
Burden
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 1
A little hard to take 4
Not at all hard to take 15
Cost per month
Cost per month Evaluations Percentage
$200+ 0
$100-199 0
$50-99 0
$25-49 5
< $25 8
Not specified 7

What people switch to and from

Patients started taking Dulaglutide after stopping:

Treatment Patients Percentage
Exenatide (Byetta) 3
Liraglutide (Victoza) 3
Metformin (Metformin ER) 2
Dapagliflozin (Farxiga) 1
Empaglifozin (Jardiance) 1

Show all 9 treatments patients report switching from

Patients stopped taking Dulaglutide and switched to:

Treatment Patients Percentage
Liraglutide (Victoza) 1
Last updated:
There are no evaluations for Dulaglutide.